Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;471(6):809-813.
doi: 10.1007/s00428-017-2222-z. Epub 2017 Aug 25.

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers' survey

Zandra C Deans  1 , Hannah Williams  2 , Elisabeth M C Dequeker  3 , Cleo Keppens  4 , Nicola Normanno  5 , Ed Schuuring  6 , Simon J Patton  7 , Melanie Cheetham  7 , Rachel Butler  8 , Jacqueline A Hall  9   10 ; IQN Path ASBL
Affiliations

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers' survey

Zandra C Deans et al. Virchows Arch. 2017 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Zandra C Deans, Hannah Williams, Cleo Keppens, Simon J Patton, Melanie Cheetham and Rachel Butler declare that they have no conflict of interest. Elisabeth MC Dequeker receives grants from Roche and Pfizer. Nicola Normanno receives grants and personal fees from AstraZeneca, Qiagen, Roche, Merck Serono, Sysmex. Ed Schuuring is on the Advisory Board and receives personal fees and travel expenses from Novartis, Pfizer and AstraZeneca and receives travel fees only for participation in an Advisory Board for Amgen. He is also on an advisory board for QCMD and receives a grant for laboratory costs. Jacqueline Hall owns stock in Vivactiv Ltd.

Figures

Fig. 1
Fig. 1
Summary of the survey results of EGFR, KRAS and NRAS mutation testing in plasma samples. Figures reported are based on the number of laboratories offering testing for either research or diagnostic use or have testing in the development phase. Note: some laboratories use testing for more than one purpose as may be seen by the intersections in the Venn diagram
Fig. 2
Fig. 2
The breakdown of methodologies used for mutation testing in plasma samples. Values represent the number of laboratories running a specific platform. Some laboratories use more than one testing method. a The current methods used for plasma ctDNA mutation testing by number of laboratories (% included). b A detailed breakdown of methods specified as “other testing methods”
See this image and copyright information in PMC

References

    1. Cree IA, Deans Z, Ligtenberg MJ, Normanno N, Edsjo A, Rouleau E, Sole F, Thunnissen E, Timens W, Schuuring E, Dequeker E, Murray S, Dietel M, Groenen P, Van Krieken JH, European Society of Pathology Task Force on Quality Assurance in Molecular Pathology, Royal College of Pathologists Guidance for laboratories performing molecular pathology for cancer patients. J Clin Pathol. 2014;67:923–931. doi: 10.1136/jclinpath-2014-202404. - DOI - PMC - PubMed
    1. Dubbink HJ, Deans ZC, Tops BB, van Kemenade FJ, Koljenovic S, van Krieken HJ, Blokx WA, Dinjens WN, Groenen PJ. Next generation diagnostic molecular pathology: critical appraisal of quality assurance in Europe. Mol Oncol. 2014;8:830–839. doi: 10.1016/j.molonc.2014.03.004. - DOI - PMC - PubMed
    1. Rolfo C, Castiglia M, Hong D, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Gil-Bazo I, Passiglia F, Carreca AP, Taverna S, Vento R, Peeters M, Russo A, Pauwels P. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Piophys Acta. 2014;1846:539–546. - PubMed
    1. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T, McCormack R. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumour DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014;9:1345–1353. doi: 10.1097/JTO.0000000000000263. - DOI - PMC - PubMed
    1. Normanno N, Rachiglio AM, Roma C, Fenizia F, Esposito C, Pasquale R, La Porta ML, Iannaccone A, Micheli F, Santangelo M, Bergantino F, Costantini S, De Luca A. Molecular diagnostics and personalised medicine in oncology: challenges and opportunities. J Cell Biochem. 2013;114:514–524. doi: 10.1002/jcb.24401. - DOI - PubMed

MeSH terms

LinkOut - more resources